Triiodothyronine-predominant Graves' disease in childhood: detection and therapeutic implications
Authors:
- Julie HarvengtJHJulie Harvengt
- Priscilla BoizeauPBPriscilla Boizeau
- Didier ChevenneDCDidier Chevenne
- Delphine ZenatyDZDelphine Zenaty
- Anne PaulsenAPAnne Paulsen
- Dominique SimonDSDominique Simon
- Sophie Guilmin CreponSCSophie Guilmin Crepon
- Corinne AlbertiCACorinne Alberti
- Jean-Claude CarelJCJean-Claude Carel
- Juliane LégerJLJuliane Léger
- 1 June 2015
- journal article
- research article
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 172 (6) , 715-723
Abstract
Objective: To assess in a pediatric population, the clinical characteristics and management of triiodothyronine-predominant Graves' disease (T3-P-GD), a rare condition well known in adults, but not previously described in children.Design: We conducted a university hospital-based observational study.Methods: All patients with GD followed for more than 1 year between 2003 and 2013 (n=60) were included. T3-P-GD (group I) was defined as high free T3 (fT3) concentration (>8.0 pmol/l) associated with a normal free thyroxine (fT4) concentration and undetectable TSH more than 1 month after the initiation of antithyroid drug (ATD) treatment. Group II contained patients with classical GD without T3-P-GD.Results: Eight (13%) of the patients were found to have T3-P-GD, a median of 6.3 (3.0–10.5) months after initial diagnosis (n=4) or 2.8 (2.0–11.9) months after the first relapse after treatment discontinuation (n=4). At GD diagnosis, group I patients were more likely to be younger (6.8 (4.3–11.0) vs 10.7 (7.2–13.7) years) and had more severe disease than group II patients, with higher serum TSH receptor autoantibodies (TRAb) levels: 40 (31–69) vs 17 (8–25) IU/l, P4 (92 (64–99) vs 63 (44–83) pmol/l) and fT3 (31 (30–46) vs 25 (17–31) pmol/l) concentrations. During the 3 years following T3-P-GD diagnosis, a double dose of ATD was required and median serum fT4:fT3 ratio remained lower in group I than in group II.Conclusion: Severe hyperthyroidism, with particularly high TRAb concentrations at diagnosis, may facilitate the identification of patients requiring regular serum fT3 determinations and potentially needing higher doses of ATD dosage during follow-up.Keywords
This publication has 25 references indexed in Scilit:
- ThyrotoxicosisThe Lancet, 2012
- Incidence of hyperthyroidism in SwedenEuropean Journal of Endocrinology, 2011
- Graves’ Disease in Childhood: Advances in Management with Antithyroid Drug TherapyHormone Research in Paediatrics, 2009
- Predictors of Autoimmune Hyperthyroidism Relapse in Children after Discontinuation of Antithyroid Drug TreatmentThe Journal of Clinical Endocrinology & Metabolism, 2008
- Predicting the Likelihood of Remission in Children With Graves’ Disease: A Prospective, Multicenter StudyPediatrics, 2008
- Graves' disease in children and adolescents: Response to long‐term treatmentActa Paediatrica, 2005
- Thyrotoxicosis in Prepubertal Children Compared with Pubertal and Postpubertal PatientsThe Journal of Clinical Endocrinology & Metabolism, 2000
- Predictors of Early Remission of Hyperthyroidism in ChildrenThe Journal of Clinical Endocrinology & Metabolism, 1997
- Hyperthyroidism in Children and AdolescentsPediatric Clinics of North America, 1990
- Management of Hyperthyroidism in Children and AdolescentsThe Journal of Clinical Endocrinology & Metabolism, 1985